Oral ulcerative mucositis is a common, painful, dose-limiting toxicity of drug and radiation therapy for cancer. This disorder is characterized by breakdown of the oral mucosa resulting in the formation of ulcerative lesions. In granulocytopenic patients, these lesions are frequent portals of entry for indigenous oral bacteria often leading to sepsis or bacteremia. Mucositis occurs to some degree in more than one third of patients receiving anti-neoplastic drug therapy. Mucositis occurs in almost all patients undergoing radiation therapy for cancer of the head and neck as well as a high percentage of patients undergoing bone marrow transplantation.
Currently, supportive care is the primary treatment option for mucositis. Patients can be prescribed analgesics for pain relief and are instructed to maintain good oral hygiene to mitigate risk of infection. Experimental compounds which modify cytokines or otherwise protect tissue from radiation or chemotherapy exposure may be efficacious for mucositis.
|The Cheek pouch is treated with an acute dose of 40 Gy radiation resulting in the formation of ulcers||28 days||Mucositis score, histology|
|The cheek pouch is treated with 8 fractions of radiation resulting in the formation of ulcers||Up to 36 days||Mucositis score, histology|
|In addition to the fractionated protocol, hamsters also receive cisplatin chemotherapy treatment||Up to 36 days||Mucositis score, histology|
|Radiation is targeted to the rodents tongue or snout and the tongue is then examined for mucositis||28 days||Mucositis score, histology|
|Chemotherapy is paired with an acute tongue injury resulting in an inflamed tongue||28 days||Mucositis score, histology|
Hamsters provide an excellent model for oral mucositis because of several biological similarities to humans. Furthermore, the cheek pouch is pliable and can be extracted such that radiation can be targeted to the cheek pouch while the rest of the animal is shielded. The result is formation of ulcers on the cheek pouch approximately 16 days following treatment. Primary end points in this model include mucositis scores based on a standardized scale and analysis of the frequency and duration of ulcers.
Patients often undergo several radiation treatments. Therefore, to model the human treatment cycle, Biomodels has developed a fractionated radiation protocol for hamster mucositis. In this protocol, the radiation treatments are divided into eight fractions over two four day cycles. The result is still the formation of ulcers on the cheek pouch, similar to the acute model, however the duration of fractionated radiation studies is typically longer. Primary end points include mucositis scores based on a standardized scale and analysis of the frequency and duration of ulcers.
In many cases, patients receive both chemotherapy and radiation therapy. Therefore, Biomodels has optimized the radiation protocol for use with combined chemotherapy. The endpoints and study duration are similar, but the expected incidence of mucositis is more severe.
In some cases, it is advantageous to study more common laboratory animals such as rats or mice. Therefore, Biomodels has developed an acute radiation model of mucositis in both rats and mice. In this model, radiation is targeted at the tongue (mice) or snout (rats). The tongue is then examined, photographed, and scored based on a standardized scale at established time points.
Mucositis is known to occur in approximately one third of patients receiving chemotherapy treatment. Biomodels has modeled chemotherapy induced mucositis in rats by combining chemotherapy administration with a small injury to the tongue. The result is an inflammation of the tongue that peaks at 5-7 days post treatment. The primary endpoints in the model include scoring the extent of injury to the tongue based on a standardized scale.
• Personalized medicine for mucositis: Bayesian networks identify unique gene clusters which predict the response to gamma-D-glutamyl-L-tryptophan (SCV-07) for the attenuation of chemoradiation-induced oral mucositis